Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
about
Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patientsEpiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report.Control of advanced cancer: the road to chronicity.A combinatorial mutagenesis approach for functional epitope mapping on phage-displayed target antigen: application to antibodies against epidermal growth factor.Lung cancer: Biology and treatment options.CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.Business models and opportunities for cancer vaccine developers.A virus-like particle-based connective tissue growth factor vaccine suppresses carbon tetrachloride-induced hepatic fibrosis in miceDegradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy.CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Actual status of therapeutic vaccination in non-small cell lung cancerImmunotherapy in lung cancer.Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.Informatics for cancer immunotherapy.Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
P2860
Q21245661-E25564EF-BAE0-45AD-B75E-B8B59DA7CF05Q27853346-A87A28BB-B67D-448A-BB7C-BE908AF04B79Q34293223-A09F337E-D603-4415-B8AB-ED2218D32EDEQ34874471-9CECEDAA-8D95-462E-A90F-1C4E9C819CD6Q35109650-196CD8F6-0C43-4806-A453-A45E2B41863DQ36328370-60905CE6-0973-4036-9FF1-30E79C6180ECQ36849784-C0D40F46-A65E-49F8-A1E8-1C2A69EA7645Q36864923-80CAFC42-FE3E-4AA7-8575-AC15D62F7ED2Q37209120-0AD7ADC9-D930-45F3-8FC6-25F1A4FA38B7Q37402532-D97FB8D5-B8BC-4691-AAC4-2360FA21D532Q37695065-B4DFEE70-EECB-44A2-B004-92DEF9149F16Q38143201-7314E26D-22BA-4A9F-A43A-2CBC3D792B78Q38223388-AC7D06D1-6F3C-42D7-8F4B-DE3925EC6777Q38390093-BB716A2C-D67F-4B81-B641-A3F0A9731F4BQ38837187-43F33A40-F11C-45D5-A68B-AF52B9535D9DQ47290509-E0240E78-82FF-44B8-BED8-4FA0090AD664Q55045138-476055BC-B906-41AB-ACA4-54E2D3D8D262
P2860
Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical development and persp ...... mall-cell lung cancer therapy.
@ast
Clinical development and persp ...... mall-cell lung cancer therapy.
@en
Clinical development and persp ...... mall-cell lung cancer therapy.
@nl
type
label
Clinical development and persp ...... mall-cell lung cancer therapy.
@ast
Clinical development and persp ...... mall-cell lung cancer therapy.
@en
Clinical development and persp ...... mall-cell lung cancer therapy.
@nl
prefLabel
Clinical development and persp ...... mall-cell lung cancer therapy.
@ast
Clinical development and persp ...... mall-cell lung cancer therapy.
@en
Clinical development and persp ...... mall-cell lung cancer therapy.
@nl
P2093
P1433
P1476
Clinical development and persp ...... small-cell lung cancer therapy
@en
P2093
Agustín Lage
Gisela González
Gryssell Rodríguez
Pedro C Rodríguez
P577
2010-01-01T00:00:00Z